Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast.
The authors studied eight cases of Churg-Strauss syndrome (CSS) associated with the use of pranlukast, a common cysteinyl leukotriene receptor antagonist (LTRA) in Japan. The patients who received pranlukast showed significantly increased peripheral blood eosinophil count, neurological disability scores, and poor responses to corticosteroid in comparison with those patients not receiving pranlukast. We suggest that preceding administration of pranlukast aggravates clinical presentations of CSS.
Shimbo
Junsuke
J
Onodera
Osamu
O
Tanaka
Keiko
K
Tsuji
Shoji
S
D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D001249:Asthma / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D002867:Chromones / Q000009:adverse effects*; D015267:Churg-Strauss Syndrome / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D012189:Retrospective Studies; D012720:Severity of Illness Index
D018927:Anti-Asthmatic Agents; D002867:Chromones; D020024:Leukotriene Antagonists; C047681:pranlukast